Stephen J. Blake

3.9k citations

36 papers · 2.3k indexed · 1 hit paper · h-index 20

Oncology top 2%
Immunology top 2%
Molecular Biology
Pulmonary and Respiratory Medicine top 10%
Physiology top 1%

Co-authors: Michele W.L. Teng Mark J. Smyth Kazuyoshi TakedaJing LiuArabella Young Shin Foong Ngiow Stacey Allen Michelle C.R. Yong
Topics: Cancer Immunotherapy and Biomarkers (13 papers)Immune Cell Function and Interaction (11 papers)Immunotherapy and Immune Responses (9 papers)
Cited by: Immunology Oncology Physiology
Journals: Nature reviews. Immunology PLoS ONE Cancer Cell
Partner nations: Australia Japan United States

In The Last Decade

Stephen J. Blake

36 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

2016 569 citations Jing Liu, Stephen J. Blake et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Stephen J. Blake

Since Specialization

Citations

This map shows the geographic impact of Stephen J. Blake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen J. Blake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen J. Blake more than expected).

Fields of papers citing papers by Stephen J. Blake

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen J. Blake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen J. Blake. The network helps show where Stephen J. Blake may publish in the future.

Co-authorship network of co-authors of Stephen J. Blake

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen J. Blake. A scholar is included among the top collaborators of Stephen J. Blake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen J. Blake. Stephen J. Blake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparing the effectiveness of calorie restriction with and without time-restricted eating on the circadian regulation of metabolism: rationale and protocol of a three-arm randomised controlled trial in adults at risk of type 2 diabetes 2025 ·Nutrition Research ·(unknown),(unknown),Xiao Tong Teong,Lijun Zhao,(unknown),Gary Wittert,(unknown),Andrew Vincent,(unknown),Morag J. Young,Stephen J. Blake,Satchidananda Panda,Emily N. C. Manoogian,Siobhan Banks,Leonie K. Heilbronn,Amy T. Hutchison	1
2	Development of a Novel Murine Model of In‐Stent Neoatherosclerosis 2025 ·Journal of the American Heart Association ·(unknown),Demeke Geremew,Lauren Sandeman,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Stephen J. Blake,Robert A. McLaughlin,Joanne T. M. Tan,Peter J. Psaltis,Claudine S. Bonder,Jiawen Li,Yanqing Wu,Christina A. Bursill	1
3	Advancing translational research for colorectal immuno-oncology 2023 ·British Journal of Cancer ·E Thomas,Josephine A. Wright,Stephen J. Blake,Amanda J. Page,Daniel L. Worthley,Susan L. Woods	20
4	OX40‐targeted immune agonist antibodies induce potent antitumor immune responses without inducing liver damage in mice 2021 ·FASEB BioAdvances ·(unknown),Stephen J. Blake,David J. Lynn	2
5	The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota 2021 ·Cell Reports Medicine ·Stephen J. Blake,(unknown),Feargal J. Ryan,José A. Caparrós‐Martín,Georgina L. Eden,(unknown),(unknown),Saoirse C. Benson,Damon J. Tumes,(unknown),Natalie E. Stevens,John Finnie,Hiroki Kobayashi,Deborah L. White,Steve Wesselingh,Fergal O’Gara,Miriam A. Lynn,David J. Lynn	26
6	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function 2019 ·Cancer Immunology Research ·Deepak Mittal,Ailin Lepletier,Jason Madore,Amelia Roman Aguilera,Kimberley Stannard,Stephen J. Blake,Vicki Whitehall,Cheng Liu,Mark Bettington,Kazuyoshi Takeda,Georgina V. Long,Richard A. Scolyer,Ruth Y. Lan,Nathan O. Siemers,Alan J. Korman,Michele W.L. Teng,Robert J. Johnston,William C. Dougall,Mark J. Smyth	90
7	Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis 2018 ·OncoImmunology ·Heidi Harjunpää,Stephen J. Blake,Elizabeth Ahern,Stacey Allen,Jing Liu,Juming Yan,Viviana P. Lutzky,Kazuyoshi Takeda,(unknown),Camille Guillerey,Deepak Mittal,Xian-Yang Li,William C. Dougall,Mark J. Smyth,Michele W.L. Teng	37
8	Comparison of multi-institutional pre-treatment verification for VMAT of nasopharynx with delivery errors 2018 ·Physica Medica ·(unknown),Sankar Arumugam,Christian Rønn Hansen,(unknown),Stephen J. Blake,(unknown),Martin Carolan,Philip Vial,(unknown),Lois Holloway,David Thwaites	8
9	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor 2016 ·Cancer Research ·Shin Foong Ngiow,Arabella Young,Stephen J. Blake,Geoffrey R. Hill,Hideo Yagita∥,Michele W.L. Teng,Alan J. Korman,Mark J. Smyth	72
10	Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer 2016 ·Cancer Research ·Jing Liu,Stephen J. Blake,Heidi Harjunpää,Kirsten A. Fairfax,Michelle C.R. Yong,Stacey Allen,Holbrook E. Kohrt,Kazuyoshi Takeda,Mark J. Smyth,Michele W.L. Teng	76
11	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy 2016 ·Cancer Discovery ·Stephen J. Blake,Kimberley Stannard,Jing Liu,Stacey Allen,Michelle C.R. Yong,Deepak Mittal,Amelia Roman Aguilera,John J. Miles,Viviana P. Lutzky,Lucas Ferrari de Andrade,Ludovic Martinet,Marco Colonna,Kazuyoshi Takeda,Florian Kühnel,Engin Gürlevik,Günter Bernhardt,Michele W.L. Teng,Mark J. Smyth	187
12	Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Diseasebreakdown → 2016 ·Cancer Discovery ·Jing Liu,Stephen J. Blake,Michelle C.R. Yong,Heidi Harjunpää,Shin Foong Ngiow,Kazuyoshi Takeda,Arabella Young,Jake S. O’Donnell,Stacey Allen,Mark J. Smyth,Michele W.L. Teng	569
13	Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity 2016 ·OncoImmunology ·Fernando Souza-Fonseca-Guimarães,Stephen J. Blake,Amani Makkouk,Cariad Chester,Holbrook E. Kohrt,Mark J. Smyth	10
14	Role of IL-17 and IL-22 in autoimmunity and cancer 2014 ·Actas Dermo-Sifiliográficas ·Stephen J. Blake,Michele W.L. Teng	32
15	A new concept in detector design for radiation therapy: Simultaneous imaging and dosimetry for comprehensive treatment verification 2013 ·Philip Vial,Stephen J. Blake,Aimee L. McNamara,Lois Holloway,Peter B. Greer,Zdenka Kuncic	3
16	Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A 2012 ·Experimental Hematology ·Stephen J. Blake,Timothy P. Hughes,A. Bruce Lyons	13
17	RNA Interference for Viral Infections 2012 ·Current Drug Targets ·Stephen J. Blake,(unknown),Nigel A.J. McMillan	16
18	Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo 2008 ·Experimental Hematology ·Cara K. Fraser,Stephen J. Blake,Kerrilyn R. Diener,A. Bruce Lyons,Michael P. Brown,Timothy P. Hughes,John D. Hayball	50
19	The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro 2008 ·Clinical Immunology ·Stephen J. Blake,Timothy P. Hughes,Graham Mayrhofer,A. Bruce Lyons	90
20	An Investigation in the Use of GPS and INS Sensors for Structural Health Monitoring 2005 ·Proceedings of the 18th International Technical Meeting of the Satellite Division of The Institute of Navigation (ION GNSS 2005) ·Chris Hide,Stephen J. Blake,Xiaolin Meng,Gethin Wyn Roberts,Terry Moore,David Park	10

About Stephen J. Blake

Stephen J. Blake is a scholar working on Immunology, Radiation and Oncology, having authored 36 papers that have together received 2.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), Immune Cell Function and Interaction (11 papers) and Immunotherapy and Immune Responses (9 papers). The work is most often cited by research in Immunology (1.1k citations), Oncology (1.3k citations) and Physiology (202 citations). Stephen J. Blake has collaborated with scholars based in Australia, Japan and United States. Frequent co-authors include Michele W.L. Teng, Mark J. Smyth, Kazuyoshi Takeda, Jing Liu, Arabella Young, Shin Foong Ngiow, Stacey Allen, Michelle C.R. Yong, Heidi Harjunpää and A. Bruce Lyons. Their work appears in journals such as Nature reviews. Immunology, PLoS ONE and Cancer Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact